<DOC>
	<DOCNO>NCT02137382</DOCNO>
	<brief_summary>maldigestion dietary macronutrients ( pancreas produce enough enzyme digestion fat , sugar protein ) Cystic Fibrosis</brief_summary>
	<brief_title>A Double-blind , Randomized , Multicenter , Cross-over Study Compare Effect Creon N Creon® Fat Digestion Subjects ≥ 12 Years Age With Pancreatic Exocrine Insufficiency Due Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Signed informed consent give subject , parent , legally acceptable representative . If require Institutional Review Board/Ethics Committee ( IRB/IEC ) , assent give subject Age ≥ 12 year Subjects able swallow capsule meal snack Diagnosis Cystic Fibrosis ( CF ) confirm two positive chloride sweat test gene analysis Diagnosis pancreatic exocrine insufficiency proven : 1 . Coefficient fat absorption ( CFA ) &lt; 70 % without supplementation 2. Human fecal elastase &lt; 50 μg/g stool Currently receive treatment commercially available pancreatic enzyme product continuous dose product 3 month Clinically stable condition without evidence acute respiratory disease within 1 month enrollment Stable body weight defined 5 % decline within 3 month enrolment Females childbearing potential agree continue use medically acceptable method birth control throughout study 30 day immediately last dose study drug . Medically acceptable method birth control include bilateral tubal ligation use either contraceptive implant , contraceptive injection ( DepoProvera™ ) , intrauterine device , oral contraceptive take within past 3 month subject agrees continue use study adopt another birth control method , doublebarrier method consist combination two following : diaphragm , cervical cap , condom , spermicide . Evidence cardiovascular , respiratory , urogenital , gastrointestinal/hepatic ( except underlie disease ) , hematologic/immunologic , head , ears , eye , nose , throat , dermatologic/connective tissue , musculoskeletal , metabolic/nutritional ( except underlie disease ) , endocrine ( except diabetes mellitus ) , neurologic/psychiatric , allergy , recent major surgery , relevant disease reveal history , physical examination and/or laboratory assessment , could limit participation completion study History acute abdomen History fibrosing colonopathy History distal intestinal obstruction syndrome ( DIOS ) within 6 month prior enrollment Solid organ transplant surgery affect large bowel appendectomy Small bowel surgery significantly affect absorptive capacity ( e.g . gastrectomy pancreatectomy ) Pregnancy lactation Any type malignancy involve digestive tract last 5 year Celiac disease Crohn 's disease Known allergy pancreatin inactive ingredient ( excipients ) pancreatin capsule Suspected noncompliance noncooperation Intake experimental drug within 30 day prior study start Mental disability lack fitness , Investigator 's opinion , preclude subject 's participation ability complete study Diagnosis human immunodeficiency virus medical history .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>maldigestion dietary macronutrients ( pancreas produce enough enzyme digestion fat , sugar protein ) Cystic Fibrosis</keyword>
</DOC>